Trial record 1 of 1 for:    renew copd
Previous Study | Return to List | Next Study

Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2012 by PneumRx, Inc.
Information provided by (Responsible Party):
PneumRx, Inc. Identifier:
First received: May 26, 2012
Last updated: September 11, 2014
Last verified: December 2012

Multicenter, randomized, assessor-blinded controlled study of safety and effectiveness of the PneumRx, Inc. RePneu Lung Volume Reduction Coil (RePneu LVRC) System

Condition Intervention Phase
Device: RePneu Lung Volume Reduction Coil System
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study

Resource links provided by NLM:

Further study details as provided by PneumRx, Inc.:

Primary Outcome Measures:
  • mean absolute change from baseline at 12 months in the 6 Minute Walk Test comparing test and control groups [ Time Frame: baseline through 12 months follow up ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mean absolute difference in SGRQ, 6MWT (responder analysis) and mean percent change in FEV1 comparing BL to 12 months, between Treatment arms. [ Time Frame: BL to 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 315
Study Start Date: October 2012
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RePneu Lung Volume Reduction Coil System
The RePneu Lung Volume Reduction Coil System is an implantable device, delivered through a fiber-optic bronchoscope. This is a two part system that consists of 1) sterile Nitinol Coils and 2) a sterile, disposable, single-use (single-patient) Delivery System consisting of a Guidewire, Catheter, Cartridge, and Forceps.
Device: RePneu Lung Volume Reduction Coil System
The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
No Intervention: Control arm is standard medical care
The Control Group will not undergo any bronchoscopies for Coil placement and will not receive prophylactic antibiotics or steroids before and after 'treatment' or chest x-rays in connection with the 'treatment' visits. The frequency of visits to the Study Doctor or designee will be similar to the LVRC Group.

Detailed Description:

This will be a prospective, multicenter, randomized, controlled study comparing outcomes between the LVRC and Control Groups. Subjects will be block randomized in an LVRC (Treatment) to Control ratio of 1:1. The randomization will be stratified by homogeneous versus heterogeneous emphysema, to support a balance of patients with differing heterogeneity in both the LVRC and Control Groups.


Ages Eligible for Study:   35 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is greater than or equal to 35 yrs of age
  • CT Scan indicates bilateral emphysema
  • Subject has post-bronchodilator FEV1 less than or equal to 45% predicted
  • Subject has Total Lung Capacity >100% predicted
  • Subject has residual volume (RV) greater than or equal to 175% predicted
  • Subject has marked dyspnea greater than or equal to 2 on mMRC scale of 0-4
  • Subject has stopped smoking for at least 8 weeks prior to entering the study as confirmed by a Cotinine test or other appropriate diagnostic test.
  • Subject has completed a pulmonary rehabilitation program within 6 mos prior to treatment and/or is regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 mos prior to baseline testing.
  • Subject has received Pneumococcal and Influenza vaccinations consistent with local recommendations and/or policy.
  • Subject (and legal guardian, if applicable) has read, understood, and signed the Informed Consent form.

Exclusion Criteria:

  • Subject has severe homogeneous emphysema determined by Core Radiology Lab.
  • Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea.
  • Subject has a change in FEV1 of greater than 20% (or, for subjects with pre-bronchodilator FEV1 below 1L, a change of greater than 200mL) post-bronchodilator unless investigator can confirm by other means that subject does not have asthma.
  • Subject has DLCO of less than 20% of predicted.
  • Subject has severe gas exchange abnormalities, PaCO2 of greater than 55mm Hg; PaO2 of less than 45 mm Hg on room air (high altitude criterion: PaO2 of less than 30mm Hg).
  • Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment.
  • Subject as severe pulmonary hypertension defined by right ventricular systolic pressure of greater than 50mm Hg and/or echocardiogram
  • Subject has an inability to walk >140m (150 yd) in 6 minutes
  • Subject has evidence of other severe disease (such as but not limited to lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study.
  • Subject is pregnant or lactating, or plans to become pregnant within the study timeframe.
  • Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia.
  • Subject has clinically significant bronchiectasis.
  • Subject has giant bullae >1/3 lung volume
  • Subject has had previous LVR surgery, lung transplantation, lobectomy or LVR devices in either lung.
  • Subject has been involved in pulmonary drug or device studies within 30 days prior to this study.
  • Subject is taking >20mg prednisone (or equivalent dose of a similar steroid) daily.
  • Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder.
  • Subject is on an antiplatelet agent (such as Plavix) or anticoagulant therapy (such as Heparin or Coumadin) which cannot be stopped for 7 days prior to the procedure.
  • Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes.
  • Subject has a sensitivity or allergy to Nickel.
  • Subject has a known sensitivity to drugs required to perform bronchoscopy.
  • Subject has been diagnosed with alpha-1 antitrypsin deficiency (AATD).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01608490

  Hide Study Locations
United States, Alabama
University of Alabama Lung Health Center Recruiting
Birmingham, Alabama, United States, 35294
Contact: Patti Smith    205-934-5555      
Principal Investigator: Mark Dransfield, MD         
United States, California
Cedars Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Rodney Mardirosian    310-967-3899   
Principal Investigator: Robert J. McKenna, Jr., MD         
El Camino Hospital/Palo Alto Medical Foundation Recruiting
Mountain View, California, United States, 94040
Contact: Juliet Wilson    650-962-4463   
Principal Investigator: Ganesh Krishna, MD         
United States, Colorado
National Jewish Health Recruiting
Denver, Colorado, United States, 80206
Contact: Carmen Egidio, RN    303-270-2622      
Principal Investigator: Ali I Musani, MD, FCCP         
United States, Connecticut
Yale University School of Medicine - Yale New Haven Hospital Recruiting
New Haven, Connecticut, United States, 06510
Contact: Christina Carbone    203-737-5040   
Principal Investigator: Gaetane Michaud, MD, MS         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Pamela Schreck, RN, MSN    866-229-6312   
Principal Investigator: Michael Jantz, MD         
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Allison S Rogowski, MS    312-965-4828   
Principal Investigator: Ravi Kalhan, MD         
University of Illinois Hospital and Health Center Recruiting
Chicago, Illinois, United States, 60612
Contact: Yvonne Valencia    312-355-5934   
Principal Investigator: Kevin Kovitz, MD         
Illinois Lung and Critical Care Institute Recruiting
Peoria, Illinois, United States, 61606
Contact: Ashley Scott, RN    309-669-1165      
Principal Investigator: William Tillis, MD         
United States, Maryland
Pulmonary and Critical Care Associates of Baltimore Recruiting
Baltimore, Maryland, United States, 21237
Contact: Stuart King    443-841-9562   
Principal Investigator: William Krimsky, MD         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: Aishatu Aloma, MBBS, MPH    617-632-8386   
Principal Investigator: Adnan Majid, MD, FCCP         
Sub-Investigator: Erik Folch         
United States, Michigan
University of Michigan Health System Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Kristine Nelson    734-232-4285   
Principal Investigator: Steven Gay, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Laura Boras    507-284-2122   
Principal Investigator: Fabien Maldonado, MD         
United States, New York
New York Presbyterian Columbia University Medical Center Recruiting
New York, New York, United States, 10032
Contact: Beth Ann Whippo    212-305-1158   
Principal Investigator: Roger Maxfield, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Emily Smathers, MPH    919-668-3812   
Principal Investigator: Momen M Wahidi, MD, MBA         
United States, Ohio
The Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Yvonne Meli    216-445-4215   
Principal Investigator: Atul Mehta, MD         
United States, Pennsylvania
Temple Recruiting
Philadelphia, Pennsylvania, United States, 19140
Contact: Helga Criner, RN    215-707-1359      
Principal Investigator: Gerard Criner, MD, FACP         
Emphysema COPD Research Center, University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Christina Ledezma, PhD    412-864-3368   
Contact: Emphysema COPD Research Center    866-948-2673   
Principal Investigator: Frank C. Sciurba, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425-6300
Contact: Danielle N. Woodford    843-792-6280   
Principal Investigator: Charlie Strange, MD         
United States, Texas
DeBakey Medical Center - VA Houston Withdrawn
Houston, Texas, United States, 77030
Pulmonary, Critical Care & Sleep Medicine Consultants,PCCS/St. Luke's Episcopal Hospital Recruiting
Houston, Texas, United States, 77030
Contact: RaLisa Parham    713-255-4000   
Principal Investigator: Timothy A Connolly, MD, FCCP         
University of Texas Health Sciences Center at San Antonio Recruiting
San Antonio, Texas, United States, 78229-3900
Contact: Regina Whitener, RN    210-250-1401   
Principal Investigator: Luis F Angel, MD         
United States, Washington
Franciscan Research Center Recruiting
Tacoma, Washington, United States, 98405
Contact: Deborah Watkins, RN, MHA    253-426-6882    deborahwatkins@fhshealth.orgorg   
Principal Investigator: Navdeep S Rai, MD, PS         
United States, Wisconsin
University of Wisconsin School of Medicine & Public Health Recruiting
Madison, Wisconsin, United States, 53792
Contact: Meghan M. Hackbarth    608-265-8765   
Principal Investigator: Scott Ferguson, MD         
Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ) Recruiting
Quebec, Canada
Contact: Josee Picard    418-656-8711 ext 2934   
Principal Investigator: Antoine Delage, MDCM         
Centre Hospitalier Universitaire de Nice Recruiting
Nice, France, CS 51069
Contact: Jennifer Griffonnet    011 33 4 92 03 82 81 ext 27 795   
Principal Investigator: Professor Charles-Hugo Marquette, MD, PhD         
CHU de Reims - Hopital Maison Blanche Recruiting
Reims, France, 51092
Contact: Delphine Gras    +33 (0) 3 26 78 78 28   
Contact: Margaux Verdier    +33 (0) 3 26 78 77 67   
Principal Investigator: Prof Gaetan Deslee, MD         
Thoraxklinik University of Heidelberg Recruiting
Heidelberg, Germany, D-69126
Contact: Brigitte Rump    +49 6221 396 8211   
Principal Investigator: Univ.- Prof. Felix JF Herth, MD, PhD         
University Medical Center Groningen Active, not recruiting
Groningen, Netherlands, 9713 GZ
United Kingdom
Royal Brompton Hospital & Chelsea Westminster Recruiting
London, United Kingdom, SW3 6NP
Contact: William McNulty, MD   
Principal Investigator: Pallav Shah, MD         
Sponsors and Collaborators
PneumRx, Inc.
Principal Investigator: Charlie Strange, MD Medical University of South Carolina
  More Information

No publications provided

Responsible Party: PneumRx, Inc. Identifier: NCT01608490     History of Changes
Other Study ID Numbers: CLN0009
Study First Received: May 26, 2012
Last Updated: September 11, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by PneumRx, Inc.:

Additional relevant MeSH terms:
Pulmonary Emphysema
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases processed this record on September 16, 2014